Related Experiment Videos
Serum sialic acid elevations in malignant melanoma patients
Cancer
|April 1, 1978
Summary
Serum sialic acid (n-acetyl neuraminic acid) is elevated in melanoma patients, potentially indicating increased tumor burden. This finding suggests serum sialic acid could serve as a clinical marker for monitoring melanoma progression or treatment response.
Area of Science:
- Biochemistry
- Oncology
- Clinical Chemistry
Background:
- Elevated membrane sialic acid (n-acetyl neuraminic acid) is often observed in malignant or transformed cells.
- Sialic acid plays a role in cellular processes and can be altered during malignant transformation.
Purpose of the Study:
- To investigate if elevated serum sialic acid concentrations are associated with malignant melanoma.
- To determine the relationship between tumor burden and serum sialic acid levels in melanoma patients.
Main Methods:
- Serum samples were collected from 30 healthy individuals and 25 patients diagnosed with melanoma.
- Sialic acid concentrations in serum were measured and compared between the two groups.
- Correlation analysis was performed to assess the relationship between sialic acid levels and tumor burden.
Main Results:
- Melanoma patients exhibited significantly higher serum sialic acid concentrations compared to normal individuals (p < 0.005).
- A trend indicated that higher sialic acid levels were associated with a larger tumor burden (p < 0.05).
Conclusions:
- Increased serum sialic acid levels are significantly associated with malignant melanoma.
- Serum sialic acid may serve as a valuable clinical biomarker for monitoring changes in tumor burden due to therapy or disease recurrence in melanoma patients.